Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

NCT03928847 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Epigallocatechin-3-gallate (EGCG)

Sponsor

Hal Chapman

Collaborators

[object Object]